Trial Profile

A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary)
Indications Carcinoma; Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

04 Aug 2026 Planned End Date changed from 1 Jul 2026 to 1 Jul 2027.
04 Aug 2026 Planned primary completion date changed from 1 Jul 2026 to 1 Jul 2027.
24 Oct 2023 According to Results presented at the 48th European Society for Medical Oncology Congress, If at least 2 responses were observed among 16 evaluable pts, the trial would proceed to the 25-patient second stage.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com